Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) Stock Price Today
Aura AI Summary
Key Stats
- $1.43BMarket Cap
- 99,204Volume
- Broad Market / FactorSector
- $124.6952W High
- $96.0652W Low
- 46 DaysTypical Hold Time
- -Enterprise Value
- -Div Yield
- -Trading Activity
Track Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Direxion NASDAQ 100 Equal Weighted Index Shares has traded between a low of $96.06 and a high of $124.69, highlighting its annual price range. Buy and sell Direxion NASDAQ 100 Equal Weighted Index Shares shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Most Recent News
First Hydrogen completes unmanned ground vehicle, gains exclusive global patent rights.
First Hydrogen Corp. has successfully built its unmanned ground vehicle (UGV), achieving a key development milestone and securing exclusive worldwide rights to the related patented technology for the patent's remaining life, with a 1% royalty on sale...

Coiled Therapeutics expects first safety data for new AO-252 cancer drug formulation by end of 2026
Coiled Therapeutics plans to report initial safety and pharmacokinetic data for its new AO-252 cancer drug formulation by the end of 2026 after dosing up to 30 patients. The new lipid-based softgel aims to improve drug absorption and consistency, wit...

Poolbeg Pharma doses 8 patients in trial to prevent cancer immunotherapy side effect CRS
Poolbeg Pharma has dosed eight patients in its TOPICAL trial testing POLB 001 to prevent cytokine release syndrome (CRS), a dangerous immune reaction caused by cancer immunotherapy. The trial targets multiple myeloma patients receiving teclistamab, a...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.